Changchun High-Tech Industry (Group) Co., Ltd. (SHE:000661)
China · Delayed Price · Currency is CNY 87.38
-0.22 (-0.25%)
At close: Feb 13, 2026
SHE:000661 Revenue
Changchun High-Tech Industry (Group) had revenue of 3.20B CNY in the quarter ending September 30, 2025, a decrease of -14.55%. This brings the company's revenue in the last twelve months to 12.88B, down -9.72% year-over-year. In the year 2024, Changchun High-Tech Industry (Group) had annual revenue of 13.47B, down -7.55%.
Revenue (ttm)
12.88B
Revenue Growth
-9.72%
P/S Ratio
2.73
Revenue / Employee
1.12M
Employees
11,547
Market Cap
35.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.47B | -1.10B | -7.55% |
| Dec 31, 2023 | 14.57B | 1.94B | 15.35% |
| Jan 1, 2023 | 12.63B | 1.88B | 17.50% |
| Jan 1, 2022 | 10.75B | 2.17B | 25.30% |
| Dec 31, 2020 | 8.58B | 1.20B | 16.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | 31.63B |
| Humanwell Healthcare (Group) | 24.18B |
| Beijing Tongrentang | 18.09B |
| Livzon Pharmaceutical Group | 11.85B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Dong-E-E-Jiao | 6.12B |
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 5.37B |
Changchun High-Tech Industry (Group) News
- 2 months ago - Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion - South China Morning Post